Cargando…

A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease

BACKGROUND: The COVID-19 has now been declared a global pandemic by the World Health Organization. There is an emergent need to search for possible medications. METHOD: Utilization of the available sequence information, homology modeling, and in slico docking a number of available medications might...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hall, Donald C., Ji, Hai-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152904/ https://www.ncbi.nlm.nih.gov/pubmed/32294562 http://dx.doi.org/10.1016/j.tmaid.2020.101646

Ejemplares similares

Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease
por: Qiao, Zhen, et al.
Publicado: (2020)

A phytochemical-based medication search for the SARS-CoV-2 infection by molecular docking models towards spike glycoproteins and main proteases
por: Pushkaran, Anju Choorakottayil, et al.
Publicado: (2021)

Molecular docking analysis of azithromycin and hydroxychloroquine with spike surface glycoprotein of SARS-CoV-2
por: Singh, Jitender, et al.
Publicado: (2021)

Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (M(pro)) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study
por: Tallei, Trina Ekawati, et al.
Publicado: (2020)

Interaction of Epigallocatechin Gallate and Quercetin with Spike Glycoprotein (S-Glycoprotein) of SARS-CoV-2: In Silico Study
por: Alavi, Mehran, et al.
Publicado: (2022)

Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease
por: Ramajayam, R., et al.
Publicado: (2010)

Inhibition of SARS-CoV-2 main protease 3CL(pro) by means of α-ketoamide and pyridone-containing pharmaceuticals using in silico molecular docking
por: Elzupir, Amin O.
Publicado: (2020)

Investigation of Cu metal nanoparticles with different morphologies to inhibit SARS-CoV-2 main protease and spike glycoprotein using Molecular Docking and Dynamics Simulation
por: Aallaei, Mohammadreza, et al.
Publicado: (2022)

In-silico approaches for identification of compounds inhibiting SARS-CoV-2 3CL protease
por: Zeyaullah, Md., et al.
Publicado: (2023)

In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy
por: Wei, Tian-zi, et al.
Publicado: (2020)

Screening of cryptogamic secondary metabolites as putative inhibitors of SARS-CoV-2 main protease and ribosomal binding domain of spike glycoprotein by molecular docking and molecular dynamics approaches
por: Prateeksha, G., et al.
Publicado: (2021)

In silico evaluation of flavonoids as effective antiviral agents on the spike glycoprotein of SARS-CoV-2
por: Jain, Anisha S., et al.
Publicado: (2021)

Screening of potential spike glycoprotein / ACE2 dual antagonists against COVID-19 in silico molecular docking
por: Yu, Ran, et al.
Publicado: (2022)

Chetomin, a SARS-CoV-2 3C-like Protease (3CL(pro)) Inhibitor: In Silico Screening, Enzyme Docking, Molecular Dynamics and Pharmacokinetics Analysis
por: Ibrahim, Mahmoud A. A., et al.
Publicado: (2023)

In-silico docking studies of selected phytochemicals against papain like protease of SARS-Cov-2
por: Saranya, Palanisamy, et al.
Publicado: (2022)

Silibinin as potential tool against SARS‐Cov‐2: In silico spike receptor‐binding domain and main protease molecular docking analysis, and in vitro endothelial protective effects
por: Speciale, Antonio, et al.
Publicado: (2021)

Comparative molecular docking analysis of the SARS CoV-2 Spike glycoprotein with the human ACE-2 receptors and thrombin
por: Bhanu, Piyush, et al.
Publicado: (2020)

Systematic virtual screening in search of SARS CoV-2 inhibitors against spike glycoprotein: pharmacophore screening, molecular docking, ADMET analysis and MD simulations
por: Dhameliya, Tejas M., et al.
Publicado: (2022)

In silico targeting SARS-CoV-2 spike protein and main protease by biochemical compounds
por: Babaeekhou, Laleh, et al.
Publicado: (2021)

Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study
por: Ramírez-Salinas, Gema Lizbeth, et al.
Publicado: (2020)

In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease
por: Xiong, Muya, et al.
Publicado: (2022)

In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors
por: Maulana, Saipul, et al.
Publicado: (2023)

In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021)

In silico investigation of potential inhibitors to main protease and spike protein of SARS-CoV-2 in propolis
por: Harisna, Azza Hanif, et al.
Publicado: (2021)

Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study
por: Coutinho, João Victor Paccini, et al.
Publicado: (2022)

Synthesis and Cytotoxic Activity of Novel Indole Derivatives and Their in silico Screening on Spike Glycoprotein of SARS-CoV-2
por: Gobinath, Perumal, et al.
Publicado: (2021)

Amentoflavone derivatives significantly act towards the main protease (3CL(PRO)/M(PRO)) of SARS-CoV-2: in silico admet profiling, molecular docking, molecular dynamics simulation, network pharmacology
por: Dey, Dipta, et al.
Publicado: (2022)

Inhibition of SARS-CoV 3CL protease by flavonoids
por: Jo, Seri, et al.
Publicado: (2019)

Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening
por: Abdusalam, Ashraf Ahmed Ali, et al.
Publicado: (2020)

Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein
por: Wrobel, Antoni G., et al.
Publicado: (2020)

Structures and dynamics of the novel S1/S2 protease cleavage site loop of the SARS-CoV-2 spike glycoprotein
por: Lemmin, Thomas, et al.
Publicado: (2020)

Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein
por: Calvaresi, Valeria, et al.
Publicado: (2023)

Corrigendum: Synthesis and Cytotoxic Activity of Novel Indole Derivatives and Their in silico Screening on Spike Glycoprotein of SARS-CoV-2
por: Gobinath, Perumal, et al.
Publicado: (2021)

In silico prediction of the inhibition of new molecules on SARS-CoV-2 3CL protease by using QSAR: PSOSVR approach
por: Madani, Achouak, et al.
Publicado: (2023)

Docking and Molecular Dynamics Simulations Clarify Binding Sites for Interactions of Novel Marine Sulfated Glycans with SARS-CoV-2 Spike Glycoprotein
por: Samanta, Priyanka, et al.
Publicado: (2023)

Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics
por: Piplani, Sakshi, et al.
Publicado: (2023)

Working goal of Brazilein sappan wood as a candidate for SARS-coV-2 antivirus drug against spike (S) glycoprotein, papain-like proteinase, and main protease: In silico study
por: Kurniawan, Entuy, et al.
Publicado: (2021)

Discovery of Camellia sinensis catechins as SARS-CoV-2 3CL protease inhibitors through molecular docking, intra and extra cellular assays
por: Liu, Shi-Yu, et al.
Publicado: (2022)

Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein
por: Johnson, Marc C., et al.
Publicado: (2020)

Expression, Glycosylation, and Modification of the Spike (S) Glycoprotein of SARS CoV
por: Shen, Shuo, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_idd183fq7iepuldh49b0crgr3s